Article Details - Overview
Oncology Briefings Vol. 6, No. 11
A Summary of a Selected Presentation From the Seventh International Kidney Cancer Symposium
September 26-27, 2008; Chicago, IL
This activity is not sanctioned by, nor a part of, the Seventh International Kidney Cancer Symposium.
Release Date: December 31, 2008
Expiration Date: December 31, 2009
Publication Overview
Authors
Medical writer: Sabeeha Muneer, PhD; Reviewed by: Gary Hudes, MD
Overview and Purpose
In 2008, an estimated 54,390 new cases of renal cell carcinoma (RCC) were expected to be diagnosed in the United States, resulting in approximately 13,000 deaths. Of these, approximately 40% will represent patients who either present with or progress to metastatic disease following nephrectomy and have a poor prognosis. The emergence of targeted agents has substantially increased the number of treatment options for patients with advanced or metastatic RCC. Three agents belonging to 2 classes of drugs, tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, have recently received US Food and Drug Administration approval for use in these patients. Several other targeted agents belonging to these 2 classes in addition to a monoclonal antibody (MoAb) targeting vascular endothelial growth factor (VEGF) have been investigated in patients with advanced RCC and are in various stages of clinical testing. In order to optimize therapies with currently available targeted agents, ongoing clinical efforts are directed toward evaluating sequential or combination antiangiogenic strategies with these agents.
The purpose of this activity is to update physicians on clinical trials on the use of targeted agents for the management of patients with advanced RCC and on studies focused on optimizing sequential or combination treatment strategies with these agents.
Target Audience
This activity is intended for medical oncologists involved in the care of patients with RCC. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Learning Objectives
Upon completion of this educational activity, you should be able to:
- Discuss the efficacy and safety of targeted agents including TKIs, anti-VEGF MoAbs, and mTOR inhibitors in the treatment of advanced or metastatic RCC
- Evaluate clinical trial data on the sequential use of TKIs, anti-VEGF MoAbs, and mTOR inhibitors in the treatment of relapsed/refractory advanced or metastatic RCC
- Assess ongoing clinical efforts to evaluate optimal combination strategies of targeted agents in advanced RCC
Instructions for Participation
- Read the following information before entering the educational activity.
- Complete the Pretest.
- Study the educational activity.
- Complete the CME test.
- Answer the evaluation questions.
- After successful completion of the CME test and evaluation, you will receive your certificate of credit online.
CME credit will be granted for only 1 form of participation, either online or via the printed publication.
You will be asked to login
or create an account.